Global Pancreatic Cancer Drugs Market Insights, Forecast to 2025

Published On: February 2020 | Report ID: 20046 | Category: Pharmaceuticals and HealthcarePages: 165

Pancreatic cancer is caused by the unrestrained growth of cells in the pancreas. This abnormal, uncontrolled growth of cells leads to the formation of lumps of tissue, commonly referred to as tumors. The presence of tumors hinders the normal functioning of pancreas.

The global Pancreatic Cancer Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pancreatic Cancer Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Pancreatic Cancer Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pancreatic Cancer Drugs in these regions.

This research report categorizes the global Pancreatic Cancer Drugs market by top players/brands, region, type and end user. This report also studies the global Pancreatic Cancer Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

Eli Lilly and Company

Celgene

Roche

Novartis

Clovis Oncology

Amgen

Merck

Teva Pharmaceutical Industries

Pfizer

PharmaCyte Biotech

Market size by Product

Drugs Approved for Pancreatic Cancer

Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)

Afinitor (Everolimus)

Erlotinib Hydrochloride

Everolimus

5-FU (Fluorouracil Injection)

Fluorouracil Injection

Gemcitabine Hydrochloride

Other

Market size by End User

Hospitals

Clinics

Market size by Region

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Europe

Germany

France

UK

Italy

Spain

Russia

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

The study objectives of this report are:

To study and analyze the global Pancreatic Cancer Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.

To understand the structure of Pancreatic Cancer Drugs market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Pancreatic Cancer Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

To project the value and sales volume of Pancreatic Cancer Drugs submarkets, with respect to key regions.

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Pancreatic Cancer Drugs are as follows:

History Year: 2014-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pancreatic Cancer Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage

1.1 Pancreatic Cancer Drugs Product

1.2 Market Segments

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Pancreatic Cancer Drugs Market Size Growth Rate by Product

1.4.2 Drugs Approved for Pancreatic Cancer

1.4.3 Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)

1.4.4 Afinitor (Everolimus)

1.4.5 Erlotinib Hydrochloride

1.4.6 Everolimus

1.4.7 5-FU (Fluorouracil Injection)

1.4.8 Fluorouracil Injection

1.4.9 Gemcitabine Hydrochloride

1.4.10 Other

1.5 Market by End User

1.5.1 Global Pancreatic Cancer Drugs Market Size Growth Rate by End User

1.5.2 Hospitals

1.5.3 Clinics

1.6 Study Objectives

1.7 Years Considered

2 Executive Summary

2.1 Global Pancreatic Cancer Drugs Market Size

2.1.1 Global Pancreatic Cancer Drugs Revenue 2014-2025

2.1.2 Global Pancreatic Cancer Drugs Sales 2014-2025

2.2 Pancreatic Cancer Drugs Growth Rate by Regions

2.2.1 Global Pancreatic Cancer Drugs Sales by Regions

2.2.2 Global Pancreatic Cancer Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

3.1 Pancreatic Cancer Drugs Sales by Manufacturers

3.1.1 Pancreatic Cancer Drugs Sales by Manufacturers

3.1.2 Pancreatic Cancer Drugs Sales Market Share by Manufacturers

3.1.3 Global Pancreatic Cancer Drugs Market Concentration Ratio (CR5 and HHI)

3.2 Pancreatic Cancer Drugs Revenue by Manufacturers

3.2.1 Pancreatic Cancer Drugs Revenue by Manufacturers (2014-2019)

3.2.2 Pancreatic Cancer Drugs Revenue Share by Manufacturers (2014-2019)

3.3 Pancreatic Cancer Drugs Price by Manufacturers

3.4 Pancreatic Cancer Drugs Manufacturing Base Distribution, Product Types

3.4.1 Pancreatic Cancer Drugs Manufacturers Manufacturing Base Distribution, Headquarters

3.4.2 Manufacturers Pancreatic Cancer Drugs Product Type

3.4.3 Date of International Manufacturers Enter into Pancreatic Cancer Drugs Market

3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

4.1 Global Pancreatic Cancer Drugs Sales by Product

4.2 Global Pancreatic Cancer Drugs Revenue by Product

4.3 Pancreatic Cancer Drugs Price by Product

5 Breakdown Data by End User

5.1 Overview

5.2 Global Pancreatic Cancer Drugs Breakdown Data by End User

6 North America

6.1 North America Pancreatic Cancer Drugs by Countries

6.1.1 North America Pancreatic Cancer Drugs Sales by Countries

6.1.2 North America Pancreatic Cancer Drugs Revenue by Countries

6.1.3 United States

6.1.4 Canada

6.1.5 Mexico

6.2 North America Pancreatic Cancer Drugs by Product

6.3 North America Pancreatic Cancer Drugs by End User

7 Europe

7.1 Europe Pancreatic Cancer Drugs by Countries

7.1.1 Europe Pancreatic Cancer Drugs Sales by Countries

7.1.2 Europe Pancreatic Cancer Drugs Revenue by Countries

7.1.3 Germany

7.1.4 France

7.1.5 UK

7.1.6 Italy

7.1.7 Russia

7.2 Europe Pancreatic Cancer Drugs by Product

7.3 Europe Pancreatic Cancer Drugs by End User

8 Asia Pacific

8.1 Asia Pacific Pancreatic Cancer Drugs by Countries

8.1.1 Asia Pacific Pancreatic Cancer Drugs Sales by Countries

8.1.2 Asia Pacific Pancreatic Cancer Drugs Revenue by Countries

8.1.3 China

8.1.4 Japan

8.1.5 Korea

8.1.6 India

8.1.7 Australia

8.1.8 Indonesia

8.1.9 Malaysia

8.1.10 Philippines

8.1.11 Thailand

8.1.12 Vietnam

8.1.13 Singapore

8.2 Asia Pacific Pancreatic Cancer Drugs by Product

8.3 Asia Pacific Pancreatic Cancer Drugs by End User

9 Central & South America

9.1 Central & South America Pancreatic Cancer Drugs by Countries

9.1.1 Central & South America Pancreatic Cancer Drugs Sales by Countries

9.1.2 Central & South America Pancreatic Cancer Drugs Revenue by Countries

9.1.3 Brazil

9.2 Central & South America Pancreatic Cancer Drugs by Product

9.3 Central & South America Pancreatic Cancer Drugs by End User

10 Middle East and Africa

10.1 Middle East and Africa Pancreatic Cancer Drugs by Countries

10.1.1 Middle East and Africa Pancreatic Cancer Drugs Sales by Countries

10.1.2 Middle East and Africa Pancreatic Cancer Drugs Revenue by Countries

10.1.3 GCC Countries

10.1.4 Turkey

10.1.5 Egypt

10.1.6 South Africa

10.2 Middle East and Africa Pancreatic Cancer Drugs by Product

10.3 Middle East and Africa Pancreatic Cancer Drugs by End User

11 Company Profiles

11.1 Eli Lilly and Company

11.1.1 Eli Lilly and Company Company Details

11.1.2 Company Business Overview

11.1.3 Eli Lilly and Company Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.1.4 Eli Lilly and Company Pancreatic Cancer Drugs Products Offered

11.1.5 Eli Lilly and Company Recent Development

11.2 Celgene

11.2.1 Celgene Company Details

11.2.2 Company Business Overview

11.2.3 Celgene Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.2.4 Celgene Pancreatic Cancer Drugs Products Offered

11.2.5 Celgene Recent Development

11.3 Roche

11.3.1 Roche Company Details

11.3.2 Company Business Overview

11.3.3 Roche Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.3.4 Roche Pancreatic Cancer Drugs Products Offered

11.3.5 Roche Recent Development

11.4 Novartis

11.4.1 Novartis Company Details

11.4.2 Company Business Overview

11.4.3 Novartis Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.4.4 Novartis Pancreatic Cancer Drugs Products Offered

11.4.5 Novartis Recent Development

11.5 Clovis Oncology

11.5.1 Clovis Oncology Company Details

11.5.2 Company Business Overview

11.5.3 Clovis Oncology Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.5.4 Clovis Oncology Pancreatic Cancer Drugs Products Offered

11.5.5 Clovis Oncology Recent Development

11.6 Amgen

11.6.1 Amgen Company Details

11.6.2 Company Business Overview

11.6.3 Amgen Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.6.4 Amgen Pancreatic Cancer Drugs Products Offered

11.6.5 Amgen Recent Development

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Company Business Overview

11.7.3 Merck Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.7.4 Merck Pancreatic Cancer Drugs Products Offered

11.7.5 Merck Recent Development

11.8 Teva Pharmaceutical Industries

11.8.1 Teva Pharmaceutical Industries Company Details

11.8.2 Company Business Overview

11.8.3 Teva Pharmaceutical Industries Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.8.4 Teva Pharmaceutical Industries Pancreatic Cancer Drugs Products Offered

11.8.5 Teva Pharmaceutical Industries Recent Development

11.9 Pfizer

11.9.1 Pfizer Company Details

11.9.2 Company Business Overview

11.9.3 Pfizer Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.9.4 Pfizer Pancreatic Cancer Drugs Products Offered

11.9.5 Pfizer Recent Development

11.10 PharmaCyte Biotech

11.10.1 PharmaCyte Biotech Company Details

11.10.2 Company Business Overview

11.10.3 PharmaCyte Biotech Pancreatic Cancer Drugs Sales, Revenue and Gross Margin (2014-2019)

11.10.4 PharmaCyte Biotech Pancreatic Cancer Drugs Products Offered

11.10.5 PharmaCyte Biotech Recent Development

12 Future Forecast

12.1 Pancreatic Cancer Drugs Market Forecast by Regions

12.1.1 Global Pancreatic Cancer Drugs Sales Forecast by Regions 2019-2025

12.1.2 Global Pancreatic Cancer Drugs Revenue Forecast by Regions 2019-2025

12.2 Pancreatic Cancer Drugs Market Forecast by Product

12.2.1 Global Pancreatic Cancer Drugs Sales Forecast by Product 2019-2025

12.2.2 Global Pancreatic Cancer Drugs Revenue Forecast by Product 2019-2025

12.3 Pancreatic Cancer Drugs Market Forecast by End User

12.4 North America Pancreatic Cancer Drugs Forecast

12.5 Europe Pancreatic Cancer Drugs Forecast

12.6 Asia Pacific Pancreatic Cancer Drugs Forecast

12.7 Central & South America Pancreatic Cancer Drugs Forecast

12.8 Middle East and Africa Pancreatic Cancer Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

13.1 Market Opportunities and Drivers

13.2 Market Challenges

13.3 Market Risks/Restraints

13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

14.1 Value Chain Analysis

14.2 Pancreatic Cancer Drugs Customers

14.3 Sales Channels Analysis

14.3.1 Sales Channels

14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.2 Data Source

16.2 Author Details

16.3 Disclaimer

Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
Choose License Type



Why Choose Us

  24/7 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Email: sales@magnifierresearch.com

Phone: +1-201-465-4211

  Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

  Information security

Your personal and confidential information is safe and secure.